Amgen has seen a fluctuating stock performance amidst various influences. The firm's
muscular disorder drug met its main goal in a late-stage study but mixed reception to its
drug study results saw the stock dip. Yet, their drugs have demonstrated promise in Phase 3 trials. Notably, Amgen gained an early victory in a lawsuit against
Regeneron over the Eylea biosimilar. Moreover,
Rocatinlimab, despite being in a competitive market, was highlighted by Goldman Sachs for its commercial potential, even though other analysts expressed concerns over the data. Moreover, Cantor analysts expressed strong optimism about Amgen's
obesity drug. The company has announced plans to present data from multiple early-stage clinical trials at ESMO 2024, suggesting a proactive scientific disclosure. Amgen also obtained approval in Japan for
Tepezza for the treatment of active thyroid eye disease, expanding its global footprint. Meanwhile, a legal update warned long-term investors who bought Amgen shares to contact the Shareholders Foundation. Finally, despite short-term headwinds, analysts remain optimistic of Amgen's long-term outlook, while they are bullish on the biodrug stock's potential yet downgraded at Leerink following Amgen’s court win over Regeneron.
Amgen AMGN News Analytics from Mon, 26 Feb 2024 08:00:00 GMT to Sun, 29 Sep 2024 16:38:29 GMT -
Rating 3
- Innovation 0
- Information -4
- Rumor -3
